CY1123950T1 - Αμινοθειολεστερικες ενωσεις ή φαρμακευτικως αποδεκτα αλατα αυτων, για χρηση στην αντιμετωπιση καρκινου - Google Patents

Αμινοθειολεστερικες ενωσεις ή φαρμακευτικως αποδεκτα αλατα αυτων, για χρηση στην αντιμετωπιση καρκινου

Info

Publication number
CY1123950T1
CY1123950T1 CY20211100206T CY211100206T CY1123950T1 CY 1123950 T1 CY1123950 T1 CY 1123950T1 CY 20211100206 T CY20211100206 T CY 20211100206T CY 211100206 T CY211100206 T CY 211100206T CY 1123950 T1 CY1123950 T1 CY 1123950T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutically acceptable
cancer
methyl
treatment
acceptable salts
Prior art date
Application number
CY20211100206T
Other languages
English (en)
Inventor
Ismail Ceylan
Gerry QUASH
Mileidys PEREZ-ALEA
Guillaume Martin
Original Assignee
Advanced Biodesign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biodesign filed Critical Advanced Biodesign
Publication of CY1123950T1 publication Critical patent/CY1123950T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με την αντιμετώπιση καρκίνου σε ένα υποκείμενο, όπου καρκινικά κύτταρα του εν λόγω υποκειμένου υπερπαράγουν Η2Ο2 και έχουν ένα επίπεδο GSH κάτω του 0,5 nmol για 25 000 κύτταρα, με αμινοθειολεστερικές ενώσεις ή φαρμακευτικώς αποδεκτά άλατα αυτών, ειδικότερα με 4-(διμεθυλαμινο)-4-μεθυλοπεντ-2-υνοθειοϊκό S-μεθυλεστέρα ή ένα φαρμακευτικώς αποδεκτό άλας αυτού, πιο συγκεκριμένα με φουμαρικό άλας S-μεθυλεστέρα του 4-(διμεθυλαμινο)-4-μεθυλο-2-πεντυνοθειοϊκού οξέος. Επίσης σχετίζεται με μια μέθοδο για επιλογή ενός υποκειμένου το οποίο πάσχει από έναν καρκίνο και το οποίο πιθανότατα θα επωφεληθεί από μια αγωγή με αμινοθειολεστερικές ενώσεις ή φαρμακευτικώς αποδεκτά άλατα αυτών, ειδικότερα με 4-(διμεθυλαμινο)-4-μεθυλοπεντ-2-υνοθειοϊκό S-μεθυλεστέρα ή ένα φαρμακευτικώς αποδεκτό άλας αυτού, πιο συγκεκριμένα με φουμαρικό άλας S-μεθυλεστέρα 4-(διμεθυλαμινο)-4-μεθυλο-2-πεντυνοθειοϊκού οξέος.
CY20211100206T 2015-10-15 2021-03-10 Αμινοθειολεστερικες ενωσεις ή φαρμακευτικως αποδεκτα αλατα αυτων, για χρηση στην αντιμετωπιση καρκινου CY1123950T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306649 2015-10-15
PCT/EP2016/074697 WO2017064247A1 (en) 2015-10-15 2016-10-14 Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1123950T1 true CY1123950T1 (el) 2022-05-27

Family

ID=54360385

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100206T CY1123950T1 (el) 2015-10-15 2021-03-10 Αμινοθειολεστερικες ενωσεις ή φαρμακευτικως αποδεκτα αλατα αυτων, για χρηση στην αντιμετωπιση καρκινου

Country Status (21)

Country Link
US (2) US20180296548A1 (el)
EP (1) EP3362056B1 (el)
JP (1) JP7062593B2 (el)
CN (1) CN108348485A (el)
AR (1) AR106352A1 (el)
CA (1) CA3001204C (el)
CY (1) CY1123950T1 (el)
DK (1) DK3362056T3 (el)
ES (1) ES2867965T3 (el)
HK (1) HK1251476A1 (el)
HR (1) HRP20210359T1 (el)
HU (1) HUE053725T2 (el)
IL (1) IL258610B (el)
LT (1) LT3362056T (el)
MX (1) MX2018004380A (el)
PL (1) PL3362056T3 (el)
PT (1) PT3362056T (el)
RS (1) RS61630B1 (el)
SI (1) SI3362056T1 (el)
WO (1) WO2017064247A1 (el)
ZA (1) ZA201802399B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101653881B1 (ko) * 2014-11-25 2016-09-02 (주)삼양세라텍 직접 가열식 온간 등방압 프레스
EP4035666A1 (en) * 2021-01-29 2022-08-03 Advanced Biodesign Aminothiolester compound or derivative thereof for use as an immunomodulatory agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011059D0 (en) * 2000-05-08 2000-06-28 Pharmacia & Upjohn Spa Use of substituted acryloyl distamycin derivatives in the treatment of tumours associated with high levels of glutathione
FR2809727B1 (fr) * 2000-05-31 2002-07-26 Galderma Res & Dev Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2842228A1 (en) * 2011-07-15 2013-01-24 University Health Network Combination treatment for cancer
EP2819993B1 (en) * 2012-03-01 2020-09-02 University Of Cincinnati Ros-activated compounds as selective anti-cancer therapeutics

Also Published As

Publication number Publication date
ZA201802399B (en) 2020-01-29
US20180296548A1 (en) 2018-10-18
JP7062593B2 (ja) 2022-05-06
HUE053725T2 (hu) 2021-07-28
AR106352A1 (es) 2018-01-03
DK3362056T3 (da) 2021-03-29
EP3362056A1 (en) 2018-08-22
HK1251476A1 (zh) 2019-02-01
CA3001204A1 (en) 2017-04-20
RS61630B1 (sr) 2021-04-29
ES2867965T3 (es) 2021-10-21
IL258610B (en) 2021-04-29
LT3362056T (lt) 2021-05-10
PL3362056T3 (pl) 2021-09-27
PT3362056T (pt) 2021-04-22
MX2018004380A (es) 2018-05-11
CN108348485A (zh) 2018-07-31
EP3362056B1 (en) 2021-02-24
CA3001204C (en) 2023-08-29
IL258610A (en) 2018-06-28
WO2017064247A1 (en) 2017-04-20
HRP20210359T1 (hr) 2021-04-16
BR112018007310A2 (pt) 2018-10-23
US20230149378A1 (en) 2023-05-18
SI3362056T1 (sl) 2021-05-31
JP2018536699A (ja) 2018-12-13

Similar Documents

Publication Publication Date Title
CY1125436T1 (el) Αναστολεις dna-pk
CY1124789T1 (el) Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CY1123852T1 (el) Αλατα ή συγκρυσταλλοι της 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
CY1118156T1 (el) Ενωσεις αντιστροφης αμιδης ως αναστολεις δεακετυλασης πρωτεϊνων και μεθοδοι χρησης αυτων
CY1121826T1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CY1120354T1 (el) Αναστολεις ακυλοτρανσφερασης της διακυλογλυκερολης 2 για χρηση στη θεραπεια μεταβολικων και συγγενων διαταραχων
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
CY1117122T1 (el) Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201691354A1 (ru) Терапевтические ингибирующие соединения
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
CY1121985T1 (el) Ρυθμιστες πρωτεοστασης
CY1124406T1 (el) Αζασετρονη για χρηση στη θεραπεια της απωλειας ακοης
CY1122024T1 (el) Ενωσεις αναστολης σηματοδοτησης μονοπατιου notch
CY1123916T1 (el) Συνδυασmος που περιλαμβανει mιa ενωση αμινοθειολεστερα ή ενα φαρμακευτικως αποδεκτο αλας αυτης και mιa ενωση ικανη αυξησης του επιπεδου η2ο2 στα καρκινικα κυτταρα ενος υποκειμενου
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
CY1123950T1 (el) Αμινοθειολεστερικες ενωσεις ή φαρμακευτικως αποδεκτα αλατα αυτων, για χρηση στην αντιμετωπιση καρκινου
CY1117654T1 (el) Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου